|
Jul 25
|
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
|
|
Jul 24
|
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
|
|
Jul 24
|
Dystrophic Epidermolysis Bullosa Market Analysis and Forecast, 2025-2035: Topical Therapies Dominate DEB Market as Vyjuvek Secures Leading Position
|
|
Jul 10
|
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
|
|
Jul 9
|
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
|
|
Jul 7
|
Exploring High Growth Tech Stocks In The US Market
|
|
Jul 7
|
High Insider Ownership In 3 Promising Growth Companies
|
|
Jun 25
|
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
|
|
Jun 25
|
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
|
|
Jun 24
|
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
|